Alto Neuroscience, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Alto Neuroscience, Inc. (ANRO) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$541.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-12
- Alto Neuroscience, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $1.21M, a 161.77% increase year-over-year.
- Alto Neuroscience, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$1.75M.
- Alto Neuroscience, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $1.74M, a 323.60% increase year-over-year.
- Alto Neuroscience, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $208.00K, a 87.26% decline year-over-year.
- Alto Neuroscience, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$289.00K, a 107.21% decline from fiscal 2024.
- Alto Neuroscience, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $4.01M.
- Alto Neuroscience, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$357.00K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$541.00K 10-Q · filed 2026-08-12 | $1.20M derived: sum of 3 quarters · filed 2026-08-12 | $1.41M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$1.75M 10-Q · filed 2026-05-13 | -$12.00K derived: sum of 2 quarters · filed 2026-05-13 | $196.00K derived: sum of 3 quarters · filed 2026-05-13 | $659.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.95M derived: sum of 2 quarters · filed 2026-03-16 | $2.41M derived: sum of 3 quarters · filed 2026-08-12 | -$289.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $208.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $671.00K derived: sum of 2 quarters · filed 2026-08-12 | -$2.03M 10-Q · filed 2025-11-12 | -$1.62M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $463.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$2.24M 10-Q · filed 2026-08-12 | -$1.83M derived: sum of 3 quarters · filed 2026-08-12 | -$194.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$2.70M 10-Q · filed 2026-05-13 | -$2.29M derived: sum of 2 quarters · filed 2026-05-13 | -$657.00K derived: sum of 3 quarters · filed 2026-05-13 | $900.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $411.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.04M derived: sum of 2 quarters · filed 2026-03-16 | $3.60M derived: sum of 3 quarters · filed 2026-03-16 | $4.01M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.19M derived: sum of 2 quarters · filed 2025-11-12 | $3.60M 10-Q · filed 2025-11-12 | $3.10M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.96M 10-Q · filed 2025-08-13 | $1.46M derived: sum of 3 quarters · filed 2025-08-13 | $2.73M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $406.00K 10-Q · filed 2025-05-14 | -$94.00K derived: sum of 2 quarters · filed 2025-05-14 | $1.17M derived: sum of 3 quarters · filed 2025-05-14 | -$125.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $762.00K derived: sum of 2 quarters · filed 2025-03-20 | -$531.00K derived: sum of 3 quarters · filed 2025-03-20 | -$357.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$31.00K derived: sum of 2 quarters · filed 2024-11-12 | $143.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.12M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $174.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |